lifestyles pharmaceuticals viagra
Sciele Pharma, Inc.(NASDAQ:SCRX) ("Sciele" or "the Company") today announced that it has acquired from Verus Pharmaceuticals, Inc.("Verus") the Twinject(R) epinephrine auto-injector (epinephrine injection, USP 1:1000) for the treatment of severe allergic reactions and anaphylaxis. Under the agreement, Sciele acquired Twinject and certain other related Verus products under development for $29 million. Verus may also receive additional payments resulting from the achievement of certain development milestones. Sales in the auto-injectable epinephrine market have increased by 17% per year over the past five years and totaled approximately $200 million in 2007, according to IMS Health(R) NPA data. Anaphylaxis is a sudden, severe, and potentially life-threatening allergic reaction triggered by exposure to one or more allergens, including foods, insect stings, drugs, and latex products. generic form of viagra does lysine affect viagra viagra print ads cialis pros and cons
